|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DTX3 |
Gene summary for DTX3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DTX3 | Gene ID | 196403 |
| Gene name | deltex E3 ubiquitin ligase 3 | |
| Gene Alias | RNF154 | |
| Cytomap | 12q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q8N9I9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 196403 | DTX3 | LZE2T | Human | Esophagus | ESCC | 7.46e-03 | 2.68e-01 | 0.082 |
| 196403 | DTX3 | LZE4T | Human | Esophagus | ESCC | 7.84e-03 | 6.74e-02 | 0.0811 |
| 196403 | DTX3 | LZE7T | Human | Esophagus | ESCC | 1.16e-09 | 4.55e-01 | 0.0667 |
| 196403 | DTX3 | LZE8T | Human | Esophagus | ESCC | 4.34e-02 | 8.34e-02 | 0.067 |
| 196403 | DTX3 | LZE24T | Human | Esophagus | ESCC | 1.20e-07 | 2.90e-01 | 0.0596 |
| 196403 | DTX3 | P1T-E | Human | Esophagus | ESCC | 3.52e-05 | 2.36e-01 | 0.0875 |
| 196403 | DTX3 | P2T-E | Human | Esophagus | ESCC | 3.73e-35 | 7.55e-01 | 0.1177 |
| 196403 | DTX3 | P4T-E | Human | Esophagus | ESCC | 3.02e-18 | 2.74e-01 | 0.1323 |
| 196403 | DTX3 | P5T-E | Human | Esophagus | ESCC | 2.53e-14 | 1.15e-01 | 0.1327 |
| 196403 | DTX3 | P8T-E | Human | Esophagus | ESCC | 3.28e-31 | 5.75e-01 | 0.0889 |
| 196403 | DTX3 | P9T-E | Human | Esophagus | ESCC | 1.27e-06 | 1.14e-01 | 0.1131 |
| 196403 | DTX3 | P10T-E | Human | Esophagus | ESCC | 1.60e-20 | 4.88e-01 | 0.116 |
| 196403 | DTX3 | P11T-E | Human | Esophagus | ESCC | 7.66e-11 | 4.32e-01 | 0.1426 |
| 196403 | DTX3 | P12T-E | Human | Esophagus | ESCC | 4.19e-32 | 6.05e-01 | 0.1122 |
| 196403 | DTX3 | P15T-E | Human | Esophagus | ESCC | 5.24e-20 | 4.66e-01 | 0.1149 |
| 196403 | DTX3 | P16T-E | Human | Esophagus | ESCC | 8.32e-27 | 5.47e-01 | 0.1153 |
| 196403 | DTX3 | P17T-E | Human | Esophagus | ESCC | 4.88e-03 | 2.49e-01 | 0.1278 |
| 196403 | DTX3 | P19T-E | Human | Esophagus | ESCC | 2.15e-06 | 3.10e-01 | 0.1662 |
| 196403 | DTX3 | P20T-E | Human | Esophagus | ESCC | 1.12e-07 | 1.01e-01 | 0.1124 |
| 196403 | DTX3 | P21T-E | Human | Esophagus | ESCC | 9.28e-06 | 1.61e-02 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000703410 | Oral cavity | OSCC | vacuolar transport | 103/7305 | 157/18723 | 1.25e-11 | 4.44e-10 | 103 |
| GO:004339318 | Oral cavity | OSCC | regulation of protein binding | 121/7305 | 196/18723 | 8.92e-11 | 2.73e-09 | 121 |
| GO:003139720 | Oral cavity | OSCC | negative regulation of protein ubiquitination | 61/7305 | 83/18723 | 1.78e-10 | 5.17e-09 | 61 |
| GO:00516074 | Oral cavity | OSCC | defense response to virus | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
| GO:01405464 | Oral cavity | OSCC | defense response to symbiont | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
| GO:200102017 | Oral cavity | OSCC | regulation of response to DNA damage stimulus | 131/7305 | 219/18723 | 3.21e-10 | 8.72e-09 | 131 |
| GO:00165746 | Oral cavity | OSCC | histone ubiquitination | 38/7305 | 47/18723 | 5.22e-09 | 1.14e-07 | 38 |
| GO:190332120 | Oral cavity | OSCC | negative regulation of protein modification by small protein conjugation or removal | 65/7305 | 95/18723 | 5.88e-09 | 1.26e-07 | 65 |
| GO:005109920 | Oral cavity | OSCC | positive regulation of binding | 105/7305 | 173/18723 | 5.88e-09 | 1.26e-07 | 105 |
| GO:00028317 | Oral cavity | OSCC | regulation of response to biotic stimulus | 177/7305 | 327/18723 | 1.73e-08 | 3.43e-07 | 177 |
| GO:00065135 | Oral cavity | OSCC | protein monoubiquitination | 47/7305 | 67/18723 | 2.32e-07 | 3.68e-06 | 47 |
| GO:00103903 | Oral cavity | OSCC | histone monoubiquitination | 24/7305 | 29/18723 | 1.74e-06 | 2.26e-05 | 24 |
| GO:00070418 | Oral cavity | OSCC | lysosomal transport | 69/7305 | 114/18723 | 2.62e-06 | 3.26e-05 | 69 |
| GO:003209210 | Oral cavity | OSCC | positive regulation of protein binding | 54/7305 | 85/18723 | 4.05e-06 | 4.71e-05 | 54 |
| GO:005143810 | Oral cavity | OSCC | regulation of ubiquitin-protein transferase activity | 37/7305 | 53/18723 | 5.37e-06 | 6.04e-05 | 37 |
| GO:00063023 | Oral cavity | OSCC | double-strand break repair | 132/7305 | 251/18723 | 7.93e-06 | 8.52e-05 | 132 |
| GO:20010227 | Oral cavity | OSCC | positive regulation of response to DNA damage stimulus | 63/7305 | 105/18723 | 1.05e-05 | 1.11e-04 | 63 |
| GO:00062825 | Oral cavity | OSCC | regulation of DNA repair | 75/7305 | 130/18723 | 1.19e-05 | 1.21e-04 | 75 |
| GO:00335233 | Oral cavity | OSCC | histone H2B ubiquitination | 12/7305 | 12/18723 | 1.24e-05 | 1.26e-04 | 12 |
| GO:00335224 | Oral cavity | OSCC | histone H2A ubiquitination | 21/7305 | 26/18723 | 1.66e-05 | 1.64e-04 | 21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa043306 | Esophagus | ESCC | Notch signaling pathway | 42/4205 | 62/8465 | 2.97e-03 | 7.97e-03 | 4.08e-03 | 42 |
| hsa0433013 | Esophagus | ESCC | Notch signaling pathway | 42/4205 | 62/8465 | 2.97e-03 | 7.97e-03 | 4.08e-03 | 42 |
| hsa043305 | Oral cavity | OSCC | Notch signaling pathway | 44/3704 | 62/8465 | 1.26e-05 | 5.55e-05 | 2.83e-05 | 44 |
| hsa0433012 | Oral cavity | OSCC | Notch signaling pathway | 44/3704 | 62/8465 | 1.26e-05 | 5.55e-05 | 2.83e-05 | 44 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DTX3 | SNV | Missense_Mutation | rs542699703 | c.130N>T | p.Arg44Trp | p.R44W | Q8N9I9 | protein_coding | tolerated(0.13) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DTX3 | SNV | Missense_Mutation | c.217N>A | p.Ala73Thr | p.A73T | Q8N9I9 | protein_coding | tolerated(0.34) | benign(0.034) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DTX3 | SNV | Missense_Mutation | c.829N>A | p.Glu277Lys | p.E277K | Q8N9I9 | protein_coding | deleterious(0.02) | benign(0.149) | TCGA-E2-A1IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| DTX3 | SNV | Missense_Mutation | c.620N>A | p.Arg207His | p.R207H | Q8N9I9 | protein_coding | deleterious(0.03) | benign(0.013) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| DTX3 | SNV | Missense_Mutation | novel | c.869N>G | p.Asp290Gly | p.D290G | Q8N9I9 | protein_coding | deleterious(0.01) | possibly_damaging(0.692) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DTX3 | SNV | Missense_Mutation | rs746868676 | c.682G>A | p.Ala228Thr | p.A228T | Q8N9I9 | protein_coding | tolerated(0.42) | benign(0.04) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| DTX3 | SNV | Missense_Mutation | rs752141567 | c.460N>T | p.Pro154Ser | p.P154S | Q8N9I9 | protein_coding | tolerated(1) | possibly_damaging(0.448) | TCGA-AY-6196-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| DTX3 | SNV | Missense_Mutation | rs201091006 | c.736G>A | p.Val246Ile | p.V246I | Q8N9I9 | protein_coding | tolerated(0.4) | benign(0.021) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| DTX3 | SNV | Missense_Mutation | rs201091006 | c.736N>A | p.Val246Ile | p.V246I | Q8N9I9 | protein_coding | tolerated(0.4) | benign(0.021) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| DTX3 | SNV | Missense_Mutation | c.166N>A | p.Glu56Lys | p.E56K | Q8N9I9 | protein_coding | tolerated(0.13) | probably_damaging(0.982) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |